David DeLucia
Vice President of Corporate FP&A and Investor Relations at FibroGen
Total operating costs and expenses for the fourth quarter of twenty twenty four were $10,300,000 compared to $66,300,000 for the fourth quarter of twenty twenty three, a decrease of $56,000,000 or 84% year over year. Total operating costs and expenses for full year 2024 were $180,000,000 compared to $369,500,000 for full year 2023, a decrease of $189,500,000 or 51% year over year. R and D expenses for the fourth quarter of twenty twenty four were $6,900,000 compared to $48,700,000 in the fourth quarter of twenty twenty three, a decrease of $41,800,000 or 86% year over year. R and D expenses for full year 2024 were $95,700,000 compared to $266,500,000 in full year 2023, a decrease of $170,800,000 or 64% year over year. SG and A expenses for the fourth quarter of twenty twenty four were $8,300,000 compared to $16,400,000 in the fourth quarter of twenty twenty three, a decrease of $8,100,000 or 49% year over year.